HOME ZACKS RESEARCH PORTFOLIO COMMUNITY BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings     EPS Surprises     Mutual Funds     Options     My Account     Help    
Zacks Elite
Zacks Elite's latest portfolio identifies companies with strong earnings growth that pay steady dividends. Click here for a two-week free trial.
Quote:
Login
Search:

Top Zacks Features
Free Membership
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
Zacks Trading Game
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Top 10 Stocks
Zacks Premium
Zacks Elite
Method for Trading
Breakout Trader
Chart Patterns Trader
Growth Trader
Momentum Trader
Options Trader
Surprise Trader
Value Trader
Value Trader 2
Partner Newsletters
Special Reports
Research Wizard

GILD: Gilead Sciences Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

GILEAD SCIENCES INC (NASD)
GILD 48.80 -0.84 (-1.69%) Vol.  2,830,438 12:17 ET

Day Low - High 48.62 - N/A
52wk Low - High 35.60 - 57.63
Avg Volume 6,894,681
Industry MED-BIOMED/GENE
Market Cap 45.19 B
Div - Yield 0.00 - 0.00
PE (forward) 17.87
PEG Ratio 1.18
Current Year Est. 2.39
EPS Last Year 1.91
Detailed Quote


Zacks Premium Research
Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 30.46%
#2 Buy 19.76%
#3 Hold 10.57%
#4 Sell 4.24%
#5 Strong Sell 2.22%
S&P 500 10.68%
Zacks Rank Guide - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations

Zacks Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

Rank in Industry

By clicking on the Rank in Industry link you will see best companies in the industry as judged by the Zacks Rank.

Zacks Rank Guide - Learn more about the Zacks Rank
Zacks Premium - The only way to get access to the Zacks Rank and Rank in Industry

Zacks Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations




BROKERAGE RECOMMENDATIONS
Current ABR 1.41
ABR (Last Week) 1.41
# of Recs in ABR 23
Average Target Price 56.00
Industry Rank by ABR 48 out of 217
Rank in Industry 63 out of 194
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate GILD?
Buy
Sell
Find out what the Zacks Community
thinks of GILD at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart
 New: Zacks Trading Game



NEWS FOR GILD
Dec 31, 2008 09:00 XplosiveStocks.com: TEVA, ITRI, SBUX, DTV, GILD, BRCM Hot Stocks on the Move
Dec 19, 2008 09:20 Beacon Equity Issues Technical Trade Alerts on Biotechnology Stocks: AMGN, CELG, GENZ, DNA, GILD, INCY
Dec 17, 2008 09:31 Seven Summits Research Releases Alerts on INTC, HIG, GILD, ALL, and MT
Dec 16, 2008 14:15 Gilead Sciences (GILD) NewsBite - GILD Upgraded By Merrill Lynch
Dec 14, 2008 23:16 ZINO Society Issues Call for Life Sciences Entrepreneurs Seeking Funding
More News

ZACKS COMMENTARY FOR GILD
Dec 24, 2008 Zacks Industry Rank Analysis: Fourth-Quarter Earnings Outlook
Dec 12, 2008 Zacks Blog: Gilead a Core Biotech Holding
Dec 12, 2008 Zacks Equity Research: Report for GILD
Oct 20, 2008 Zacks Blog: Gilead Offers Opportunities
Sep 08, 2008 Zacks Blog: Gilead Sciences a Core Biotech
More Commentaries

EARNINGS ESTIMATES
  This Quarter
12/2008
Next Quarter
03/2009
This Year
12/2008
Next Year
12/2009
Average Estimate 0.55 0.59 2.04 2.39
Number of Estimates 25 6 24 24
Low Estimates 0.51 0.56 2.00 2.24
High Estimate 0.60 0.62 2.09 2.55
Year Ago EPS 0.41 0.51 1.68 2.04
EPS Growth 33.46% 16.01% 21.45% 17.24%

More Estimates

COMPANY DESCRIPTION
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.

Full Company Report
FINANCIALS
EPS TTM 1.91
Sales 4230.04
Net Income 1844.6
Price/Earnings 25.98
Price/Book 10.96
Price/Cash Flow 27.72
Price/Sales 9.03


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research